Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

FDA Accepts sBLA for Adjuvant Ipilimumab in Melanoma

March 2nd 2015

The FDA has accepted a supplemental Biologics License Application for ipilimumab for the adjuvant treatment of patients with stage III melanoma at high risk of recurrence following complete resection.

GSK, Novartis Product Exchange Completed

March 2nd 2015

GlaxoSmithKline (GSK) and Novartis have announced that a multi-billion-dollar, 3-pronged deal to exchange and share various operations has been completed.

FDA Approvals, Breakthrough Designations, Priority Reviews, and More

February 27th 2015

Five-Year Analysis Shows Ipilimumab More Than Doubles OS in Advanced Melanoma

February 27th 2015

In an analysis of phase III data, the 5-year survival rate with ipilimumab plus dacarbazine in patients with advanced melanoma was 18.2% versus 8.8% with dacarbazine alone.

PD-1 Inhibition Requires Further Refinement in Melanoma

February 25th 2015

In an interview with OncLive, Suzanne L. Topalian, MD, director of the Melanoma Program at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discussed the rapid advance of nivolumab and potential next-steps.

Closing Comments: Updates in Malignant Melanoma

February 24th 2015

Emerging Therapies for Malignant Melanoma

February 24th 2015

Adjuvant Immunotherapy for Melanoma

February 24th 2015

Earlier Use of Checkpoint Inhibitors in Melanoma

February 24th 2015

Combination Therapies for Metastatic Melanoma

February 24th 2015

Multidisciplinary Care for Malignant Melanoma

February 24th 2015

Measuring Response to Immunotherapy in Melanoma

February 24th 2015

Managing Toxicity of Immunotherapy in Melanoma

February 24th 2015

Treatment Duration for PD-1 Inhibitors in Melanoma

February 24th 2015

Immunotherapy in BRAF Wild-Type Advanced Melanoma

February 24th 2015

Frontline Therapy for BRAF-Mutated Unresectable Melanoma

February 24th 2015

Treatment Approaches for Resectable Melanoma

February 24th 2015

Cobimetinib Receives Priority Review for Advanced Melanoma

February 19th 2015

The FDA has granted a priority review to the MEK inhibitor cobimetinib for use in combination with the BRAF inhibitor vemurafenib (Zelboraf) to treat patients with BRAF V600â€“positive advanced melanoma.

FDA Schedules Advisory Meeting for T-VEC in Metastatic Melanoma

February 12th 2015

The FDA has scheduled an advisory hearing to discuss the biologics license application for the immunotherapy talimogene laherparepvec as a treatment for patients with metastatic melanoma.

Novel Molecular Test Contributes to Definitive Diagnosis in Melanoma

February 12th 2015

The Myriad myPath Melanoma molecular diagnostic test was effective in helping practitioners differentiate between benign and malignant melanocytic lesions, according to results from a prospective study.